Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2570

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2570
---
 identification, discovery and preclinical
and clinical development of certain of our product candidates, these product candidates may not be safe or effective as cancer treatments,
and we may not be able to develop any other product candidates. Although we analyze whether we can replicate scientific results observed
prior to our acquisition or investment in a product candidate, we may not be successful in doing so after our investment. Our differentiated
business model is evolving and may not succeed in building a pipeline of product candidates. Even if we are successful in building our
pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate
acceptable clinical data, including as a result of unacceptable toxicity or other characteristics that indicate that they are unlikely
to receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop
and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant
harm to our financial position and adversely affect our stock price.

Additionally,
we may pursue additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. While
we believe our subsidiary model offers an attractive platform for these transactions and for potential partners, our model is unique
and we may not be able to attract or execute transactions with licensors or collaborators who may choose to partner with companies that
employ more traditional licensing and collaboration approaches. Identifying, selecting, and acquiring promising product candidates requires
substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license
of a successful product candidate, potentially resulting in a diversion of our management’s time and the expenditure of our resources
with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend
material amounts of our capital and other resources evaluating, acquiring, and developing products that ultimately do not provide a return
on our investment. We expect to terminate programs in the future if they do not meet our criteria for advancement.

Our
subsidiaries are party to certain agreements that provide our licensors, collaborators or other shareholders in our subsidiaries with
rights that could delay or impact the potential sale of our subsidiaries or could impact the ability of our subsidiaries to sell assets,
or enter into strategic alliances, collaborations or licensing arrangements with other third parties.

69

Each
of our subsidiaries directly or indirectly licenses intellectual property from third parties and, future subsidiaries may be partially
owned by third